| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IRAK1BP1 |
| Uniprot No | Q5VVH5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-260aa |
| 氨基酸序列 | MSLQKTPPTR VFVELVPWAD RSRENNLASG RETLPGLRHP LSSTQAQTAT REVQVSGTSE VSAGPDRAQV VVRVSSTKEA AAEAKKSVCR RLDYITQSLQ QQGVQAENIT VTKDFRRVEN AYHMEAEVCI TFTEFGKMQN ICNFLVEKLD SSVVISPPQF YHTPGSVENL RRQACLVAVE NAWRKAQEVC NLVGQTLGKP LLIKEEETKE WEGQIDDHQS SRLSSSLTVQ QKIKSATIHA ASKVFITFEV KGKEKRKKHL |
| 预测分子量 | 29,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Characterization of IRAK1BP1 in Toll-like Receptor Signaling"**
*作者：Li X et al.*
摘要：研究通过重组IRAK1BP1蛋白分析其在TLR/IL-1R信号通路中的作用，发现其通过抑制IRAK1磷酸化负调控NF-κB激活，影响炎症反应。
2. **"Expression and Functional Analysis of Recombinant IRAK1BP1 in Autoimmune Disorders"**
*作者：Park JH et al.*
摘要：利用大肠杆菌系统表达重组IRAK1BP1.证实其通过调节STAT1通路抑制自身免疫模型中的过度炎症反应，提示其治疗潜力。
3. **"Structural Insights into IRAK1BP1 Interaction with IRAK1"**
*作者：Chen R et al.*
摘要：通过X射线晶体学解析重组IRAK1BP1与IRAK1的复合物结构，揭示其结合界面关键残基，为靶向药物设计提供结构基础。
4. **"IRAK1BP1 Modulates Antiviral Innate Immunity via TRAF3 Ubiquitination"**
*作者：Wang Y et al.*
摘要：研究发现重组IRAK1BP1蛋白通过促进TRAF3泛素化增强I型干扰素产生，证实其在RNA病毒免疫应答中的调控作用。
IRAK1BP1 (Interleukin-1 Receptor-Associated Kinase 1-Binding Protein 1), also known as SIMPL (Signaling Molecule Involving IRAK1 and PLD2), is a regulatory protein involved in innate immune signaling pathways. It functions as a scaffold or adaptor protein, modulating interactions between key signaling components. Structurally, it contains a conserved N-terminal region and a C-terminal domain critical for binding partners like IRAK1. PLD2. and TRAF6.
IRAK1BP1 plays a role in Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling by influencing NF-κB and MAPK activation. It acts as a negative regulator, dampening excessive inflammatory responses by interfering with IRAK1 activity or promoting its degradation. This regulation helps maintain immune homeostasis, preventing hyperactivation linked to autoimmune diseases or chronic inflammation. Studies suggest its involvement in apoptosis, cell proliferation, and antiviral responses.
Dysregulation of IRAK1BP1 has been associated with autoimmune disorders (e.g., systemic lupus erythematosus), cancers, and neurodegenerative conditions. In SLE patients, reduced IRAK1BP1 expression correlates with disease severity. Recombinant IRAK1BP1 proteins are engineered in systems like *E. coli* or mammalian cells, enabling functional studies, structural analysis, and drug screening. These tools help elucidate its interactions, post-translational modifications, and therapeutic potential.
Overall, IRAK1BP1 recombinant proteins are vital for dissecting immune signaling mechanisms and developing targeted therapies for inflammation-related diseases.
×
